DiaMedica Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

DiaMedica Therapeutics

03/11/2021 10:44

* DiaMedica Therapeutics Inc  DMAC.OQ   DMAC.O  is expected
to show no change in quarterly revenue when it reports 
results on November 3 (estimated). 
​* Refinitiv's mean analyst estimate for DiaMedica Therapeutics
Inc is for a loss of 23 cents per share. For the same quarter
last year, the company reported a loss of 19 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for DiaMedica
Therapeutics Inc is $21​, about 79.9% above​ its last closing
price of $4.22. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.20       -0.21      -0.17     Beat    19.7
 Mar. 312021   -0.21       -0.21      -0.19     Beat    10.9
 Dec. 312020   -0.18       -0.17      -0.23     Missed  -36.9​
 Sep. 302020   -0.15       -0.15      -0.19     Missed  -29.5
 ​​Jun.        -0.16       -0.15      -0.17     Missed  -10.9
 302020                                                 
 Mar. 312020   -0.27       -0.28      -0.19     Beat    32.9​
 Dec. 312019   -0.25       -0.25      -0.21     Beat    15.6
 Sep. 302019   -0.21       -0.21      -0.20     Beat    4.8
 This summary was machine generated November 3 at 10:43 GMT.  All
figures in US dollars unless otherwise stated